CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue, net	$ 25,767,000	$ 11,185,000
Operating expenses:
Costs of goods sold, including related party expenses of $1,027 and $447, respectively	27,558,000	9,983,000
Selling, general and administrative, including related party expenses of $504 and $494, respectively	99,135,000	71,041,000
Research and development, including related party expenses of $231 and $255, respectively	18,613,000	12,867,000
Amortization of intangible assets	2,267,000	2,267,000
Total operating expenses	147,573,000	96,158,000
Loss from operations	(121,806,000)	(84,973,000)
Change in the fair value of earnout liability	58,308,000
Change in the fair value of convertible promissory notes	(2,559,000)	(128,000)
Change in the fair value of warrants	7,084,000	(7,646,000)
Interest expense, net	(991,000)	(1,364,000)
Other income, net	4,664,000	781,000
(loss) income before income taxes	(55,300,000)	(93,330,000)
Provision for income taxes	480,000	17,000
Net loss	(55,780,000.00)	(93,347,000)
Accretion of Legacy Gelesis senior preferred stock to redemption value	(37,934,000)	(94,134,000)
Accretion of noncontrolling interest put option to redemption value	(253,000)	(376,000)
Income allocated to noncontrolling interest holder	(1,095,000)
Net loss attributable to common stockholders	$ (95,062,000)	$ (187,857,000)
Net loss per share attributable to common stockholders - basic	$ (1.35)	$ (32.89)
Net loss per share attributable to common stockholders - diluted	$ (1.35)	$ (32.89)
Weighted average common shares outstanding, basic	70,300,772	5,712,042
Weighted average common shares outstanding, diluted	70,300,772	5,712,042
Product Revenue, Net
Revenue:
Total revenue, net	$ 25,558,000	$ 11,185,000
Licensing Revenue
Revenue:
Total revenue, net	$ 209,000